6640--CTX Biorad Bioplex
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
SUBJECT: Sources Sought Immunoassay Random Access Multiplex Analyzer
1. PURPOSE
The Department of Veterans Affairs, South Texas Network Contracting Office, on behalf of the Central Texas Veterans Health Care System (CTVHCS), Pathology & Laboratory Medicine Service (P&LMS), is seeking information from qualified sources capable of providing a fully automated, random-access multiplex immunoassay analyzer system to replace existing end-of-life immunoassay equipment. This request for information is issued for market research and planning purposes only and does not constitute a solicitation or a commitment by the Government to award a contract.
The Government is specifically seeking information from Small Businesses (SB), Service-Disabled Veteran Owned Small Businesses (SDVOSB), and Veteran Owned Small Businesses (VOSB) that can provide equipment and services meeting the minimum technical requirements outlined below.
2. BACKGROUND
CTVHCS requires replacement of existing multiplex immunoassay testing equipment that has reached the end of its economic lifecycle. The replacement system is needed to maintain accurate, reliable autoimmune, infectious disease, and specialty immunoassay testing in support of patient care in the VA clinical laboratory environment.
3. MINIMUM TECHNICAL REQUIREMENTS
The requested solution is an Immunoassay Random Access Multiplex Testing Instrumentation System that meets or exceeds the following minimum requirements derived from the Statement of Objectives:
a. System Type
Fully automated, random access multiplex immunoassay analyzer suitable for clinical laboratory use.
Capable of consolidating autoimmune, infectious disease, and specialty immunoassay testing on a single platform.
b. Testing Capabilities
FDA approved analyzer capable of analyzing both Total Syphilis (IgG/IgM) and RPR.
Supports testing for autoimmune markers, infectious disease markers, and other specialty immunoassays as defined in the offered test menu.
Provides programmable priority testing for STAT samples (ability to prioritize STAT specimens within routine workflow).
Includes integrated quality control functionality, allowing performance of quality control checks and documentation of QC results.
c. Sample Handling and Utilities
Accepts CLSI (Clinical & Laboratory Standards Institute) standard specimen tubes.
Operates on a 110volt power system.
Includes an uninterruptible power supply (UPS) appropriate for the offered instrument.
Provides a user interface for programming and operation; a touchscreen interface is preferred but not mandatory.
d. Installation / Site Requirements
Vendor shall provide delivery, installation, and initial operational checks at:
Pathology & Laboratory Medicine Service
Central Texas Veterans Health Care System
1901 Veteran s Memorial Dr.
Temple, TX 76504
Installation shall include removal and appropriate handling/disposition of the existing end-of-life cycle analyzer (Government equipment ID EE# 152362) in coordination with facility procedures.
4. VENDOR RESPONSE REQUEST
Interested vendors are requested to submit a capability statement that addresses the following:
a. Company Information
Legal company name, address, and UEI number.
Point of contact name, title, phone number, and email.
Business size and socioeconomic status under NAICS 334516 (or recommended NAICS), including indication if your firm is:
Large Business
Small Business (SB)
Service-Disabled Veteran Owned Small Business (SDVOSB)
Veteran Owned Small Business (VOSB)
Confirmation of current registration in SAM and, if applicable, in the VA VetCert database for SDVOSB/VOSB status.
b. Technical Capability
Manufacturer and model of the proposed immunoassay random-access multiplex analyzer system.
Description of how the proposed system meets or exceeds each of the minimum technical requirements listed in Section 3 (address each bullet explicitly).
Summary of available test menu, including autoimmune, infectious disease, and specialty immunoassay assays.
Description of STAT testing capability and workflow (how STAT samples are prioritized).
Overview of onboard QC capabilities and how QC results are documented and managed.
c. Installation and Support
Description of delivery, installation, and training services available for the Temple, TX location.
Estimated delivery and installation lead time from receipt of order.
Summary of warranty, maintenance, and service support options (e.g., onsite service coverage, response times, remote support).
d. Contracting Information
Identification of any existing Federal Supply Schedule (e.g., VA FSS or GSA) or other Government contract vehicles on which the proposed equipment and services are available.
Indicate whether your firm intends to provide the system as an OEM manufacturer or as an authorized distributor/reseller (include documentation of authorized reseller status if applicable).
5. RESPONSE FORMAT AND DUE DATE
Responses should be submitted electronically in PDF or Word format via email.
Include RFI Immunoassay Random Access Multiplex Analyzer Replacement CTVHCS in the subject line.
Page limit (recommended): 10 pages or fewer.
Responses are requested no later than 01/09/2026, to:
Ognian D. Ivanov
ognian.ivanov@va.gov
6. DISCLAIMER
This Sources Sought is issued solely for information and planning purposes and does not constitute a solicitation. No contract will be awarded from this announcement. Responding to this Sources Sought is strictly voluntary and the Government will not pay for any information or administrative costs incurred in response. Responses may be used to inform acquisition strategy, including potential set-aside determinations.